



Product Data Sheet

□ Cat # RP-909

Recombinant Human CD21 protein

Size: □ 2 ug

CD21 is expressed strongly on mature B cells, follicular dendritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CD21 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CD21 expression is also gradually lost after stimulation of B cells in vitro. CD21 functions as receptor for C3d, C3dg and iC3b Complement components, for EBV and for IFN-alpha. CD21 binds to CD23 and associates with CD19, CD81 and Leu13 to form a large signal-transduction complex involved in B cell activation.

Synonyms Complement receptor type 2, Cr2, Complement C3d receptor, Epstein-Barr virus receptor, EBV receptor, CD21 antigen, CR2, C3DR, CD21, SLEB9.

SOURCE:

Human CD21 protein (protein accession # P20023, 21-971 aa, His tag, Mol wt ~135 Kda) was produced in CHO cells and purified (>95%). The protein is supplied in PBS, pH 7.4 is liquid or powder form (see lot sp. conc on the vial). Reconstitute powder in PBS at least 10 ug/ml.

APPLICATION AND SUGGESTED DILUTIONS:

Greater than 95.0% as determined by SDS-PAGE. Users must optimize the appropriate concentration and conditions for each assay. It is recommended for use in ELISA or Western as positive control.

STORAGE & STABILITY:

Store at -20oC and stable for 6 months in the original vial. Reconstituted protein should be stored at -20oC or below and stable for 3 months.

USAGE:

This item is for LABORATORY RESEARCH USE ONLY.

Refs: Tanner J (1987) Cell 50, 203; Sengstake S (2006) JBC 265, Intl. Immunol. 18, 1171; Dempsey PW (1996) Science 271, 348

Related Items

CD21F-100	Anti-Human CD21-FITC conjugate
CD21F-25	Anti-Human CD21-FITC conjugate
CD21P-100	Anti-Human CD21-PE conjugate
CD21P-25	Anti-Human CD21-PE conjugate
CD21PC-100	Anti-Human CD21-PE-Cy5-conjugate
CD21PC-25	Anti-Human CD21-PE-Cy5-conjugate
CD21UL-100	Anti-Human CD21, Unlabeled

RP-909 101111A